TheEdgeResearch
Home / Stocks / AOXG

Aoxing Pharmaceutical Company, Inc. (AOXG)

OTC Healthcare Medical - Pharmaceuticals
$0.00 ▲ +0.00%
Market Cap
$1.3M
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Beta
3.74
52-Wk Range
0.0016-0.0107
CEO
Zhenjiang Yue
Country
US
Currency
USD

Aoxing Pharmaceutical Company, Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Foster City, CA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $1.3M. On trailing twelve-month figures it carries a trailing P/E of -86.98, a net margin of -79.5%. Its beta of 3.74 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-86.98
Price / Sales
69.16
Price / Book
-244.14
EV / EBITDA
-92.14
Gross margin
88.1%
Operating margin
-79.5%
Net margin
-79.5%
Return on equity
Debt / equity
-18.82
Current ratio
0.96
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
Other OTC
Employees
346
IPO date
2005-02-21
Headquarters
Foster City, CA, US
About Aoxing Pharmaceutical Company, Inc.

Aoxing Pharmaceutical Company, Inc. is a specialized drug manufacturer primarily operating within the People's Republic of China. The company dedicates itself to the research, development, production, and distribution of pharmaceutical products, with a strong emphasis on narcotics, pain management solutions, and addiction treatments. Its current product portfolio includes Zhongtong'an, a capsule derived from herbal extracts used for relieving oral and dental discomfort; Yiqi Qiangshen Granule, an over-the-counter herbal preparation designed to invigorate qi, strengthen the body, and improve blood flow by clearing meridian blockages; and Tilidine hydrochloride. The latter is an oral synthetic narcotic analgesic tablet, available in 50mg or 100mg doses, prescribed for the alleviation of acute, moderate to severe pain, as well as chronic pain associated with cancer. Aoxing also boasts several promising products in its development pipeline. These include Oxycodone and Acetaminophen tablets and capsules, which have successfully completed clinical trials for both acute and chronic pain management. Another is Buprenorphine/Naloxone, a sublingual combination tablet that has finished Phase II clinical trials as a treatment for opioid dependence. Furthermore, a Tilidine/Naloxone compound capsule is currently undergoing Phase II clinical trials, targeting acute and chronic pain. Initially known as China Aoxing Pharmaceutical Company, Inc., the firm rebranded to Aoxing Pharmaceutical Company, Inc. in March 2010. Its corporate headquarters are situated in Shijiazhuang, China.

Comparable companies

Aoxing Pharmaceutical Company, Inc. is most often compared with the following Healthcare names:

AREVFCWWBFFFNTFHMPQNBIOPZOORLBDSFLMVDRMVIVXF
More research on AOXG
AOXG technical analysis AOXG TheEdge Score Compare against peers
Open full interactive analysis & DCF →